Member Info for Soupdragon78

Currently a smidge below 80% of shares in issue churned by volume since 7 April. (471.3m shares out of 591.6m)

Thanks Kane, interesting links.

As you note the report is auto generated and will always date at the time you click the link.

The interesting documents are attached to the first link. These show the documentation and report written as part of the PCT.
a bit too parent lawyer geeky for my level of understanding, but worth a read.

Whilst NFX have said there will be nothing material in future from Ebers, I’m keeping my eye on this documentation as the proceed to list as I wouldn’t put it past them to try something.

FX, Kelly Ventures was set up for the sole purpose of allowing a reverse takeover by another company (not specifically Ebers but that is what has transpired) hence they don’t have a website.

From the docs

“ The Ebers Acquisition will not constitute a non-arm’s length transaction, and as such will not require the approval of the Company’s shareholders.”

FX, Ebers have taken down their website. They are still going through the process of RTO into Kelly Ventures and have extended out their period to do so until end of September.
Kelly Ventures shareholders have a general meeting at the end of this month to vote on the process although they cannot stop it.
After this the prospectus will be posted so we will see their real intentions.

Latest info on Sedar

https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00045877

In a shortened version, NFX have 2 patents relating to NXP002.

1 - Tranilast compositions and cocrystals - This was filed in 2012 and has been granted across numerous jurisdictions including the US in 2018. It covers the ability to create cocrystals formed with Tranilast.

2 - Crystalline tranilast salts and their pharmaceutical use - Filed in 2018 and is the patent recently given notification of allowance in the US. It is still undergoing assessment in other countries. This patent covers the numerous delivery methods and methods of treament using tranilast cocrystals.

Whilst I'm not patent lawyer and others may know more, I think it works in the following way.

The company files for a 'global patent' with the World Intellectual Property Organisation (WIPO), they operate with the Patent Cooperation Treaty, which acts as a central point for patent applications.

First an International Search is carried out by WIPO, this looks at technical docs and other patents to see if your item is patentable.

At the end of the PCT procedure, you must decide whether to continue pursuing protection for your invention and in which countries. If you decide to move forward, you will need to “enter the national phase” with your PCT application, where each national or regional office you select will assess your patent application.

In the national phase, the national and regional patent Offices assess your patent application according to their national laws and procedures, taking into account the results of the PCT search and examination received from WIPO.

So whilst we have seen the 'world patent' published for Crystalline tranilast etc, it still goes through each national patent body separately. The benefit to getting the allowance from the US first is it helps other patent bodies speed up their process.

FX, I guess there may be clauses in the option to time limit discussions. You could have a clause saying 'upon granting of option, both parties have 3 months to conclude licensing discussions'

Also, Oxilio may not have access to the required information until the licensing is complete, so its in their interest to conclude as they might not be able to carry out their desired work until agreement has been reached.

Cuddo,

I had a dig around and the typical timeline for the patent being granted following the 'Notification of Allowance' is around 12 weeks at the quickest. So will be September time we hear on that front.

£195,550 will be my guess.

Based on that was the H1 figure and there we no revenue generating events to end of March. Oxilio make their second payment upon signing the licensing, they didn't pay at point of taking up the option in March.

Thanks Older, Interesting point re. Kidlington.

I was trying to see if there was anything between Oxilio and Ebers which might link to Oxilio funding. As we know they need more cash to carry out the licensing and also to carry out the clinical work.
As this dragged on, it is getting closer to the point in time where Eber list on TSX raising (my guesstimate) $50m. My conspiracy theory was wondering whether Oxilio were a stop gap to acquire NFX tech piecemeal?

All just conjecture on my part on a night without footie.

"As Ebers has not yet completed its audited financial statements for the years ended March 31, 2020, and 2021, as required to complete the Filing Statement for the TSXV, the Company and Ebers have agreed to extend the outside date for closing the definitive amalgamation agreement to September 30, 2021"

More of a sign that I'm bored and there's nothing new to latch onto out there at the minute, but its interesting to see that Ebers are positioning themselves as 'Pharma Tech' now and less about the cannabinoids. They are selling themselves purely about developing cocrystal technology.

"As previously announced, Ebers is a Canadian registered Pharma Tech company, with a portfolio of patents and development methods for producing cocrystals. Ebers is strategically positioned at the nexus of the big pharmaceutical and cocrystal industries, enabling the Company to play a crucial role in the development of the next generation of pharmaceuticals and therapies, and to simultaneously exploit the rapidly advancing cannabinoid and psilocybin cocrystal, pharmaceutical and wellness areas. Of these, the most widely studied and used application is in drug development and more specifically, the formation, design, and implementation of active pharmaceutical ingredients. For further details of Ebers and a summary of the Qualifying Transaction, please refer to the Company’s News Release of December 21, 2020. "

I was trying to find if there was any link between Oxilio and Ebers, just out of curiosity. Can only find that Ralph Browning of Oxilio and Pascal Hughes of Ebers worked at Deutsche in the 90's but not whether in the same sector. Had also wonder it DT knew Yaxley which is likely given their status over the past decade.

Reason being, I was increasingly suspicious that Oxilio were a front for Ebers who are raising money through a listing on TSX, which coincidentally today has been pushed back further due to Ebers not filing their accounts for the past two years.

Seems to have scared everyone off now. All gone very quiet.

Indeed filter, one eyebrow raised on those trades at the moment due to lack of follow up. Its been a feature of recent trading here to use a big trade to spark interest then batch sell.
Any leak would have greater following tail wind than this.

Somebody is happy enough to buy 1m and 500k within seconds of each other.

In answer to your DG questions cuddo.
No.
No. Check which director sold shares within 2 weeks of the leak but didn’t declare for another 6 months.

The company received milestone payments. New summit had been cooking the books and were shut down by their parent company. Nothing to do with DG. Hence DT left the same week it came to light that he sold shares without notifying.

He’s been taken off their website.

LinkedIn is up to the individual to update, hence Keegan still says he’s at NFX.

FX, interesting to see DG is no longer involved with Qureight and is just a freelance consultant at the moment. Has his own company now LSHS Consulting Ltd.

Just need all involved to sharpen their pencils and sort out the NXP001 license, even I'm getting frustrated now after 3 months from them 'starting discussions'.
Need to be getting to a point of turning away from Ox if they are struggling to get the cash together rather than end up with a deal that's as bad as something Boris would come up with.